All Resources

Economic Impact • June 12, 2025

Open Letter

Learn more | View

Access to Medicine • March 10, 2025

Increasing Access to Innovative Medicines

Written Submission for the Pre-Budget Consultations in Advance of the Upcoming Federal Budget…

Learn more | View

Intellectual Property • November 06, 2024

Submission on Global Affairs Canada CUMSA Consultation

Learn more | View

Intellectual Property • April 16, 2024

IMC Response to Consultation on Scientific Research and Experimental Development

Learn more | View

September 08, 2023

Submission on Consultation regarding Patent Term Adjustment (PTA) Regulations

Learn more | View

Intellectual Property • July 07, 2023

Consultation on Competition Policy – Submission of IMC

Learn more | View

Intellectual Property • July 07, 2023

Comments on the Public Health Agency of Canada’s Pandemic Instrument Partner and Stakeholder Engagement Forum

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • December 05, 2022

The Suspension and Reformulation of the PMPRB Guidelines is Urgently Required: IMC Response to PMPRB 2022 Guidelines Proposals

Learn more | View

Access to Medicine • February 05, 2022

Bluesky Project

Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022…

Learn more | View

Ethics • January 01, 2022

2022 Code of Ethical Practices

Learn more | View

Access to Medicine • August 06, 2021

2022 Federal Pre-Budget Consultation

Learn more | View

Economic Impact • May 30, 2021

The Canadian Research and Development Pharmaceutical Sector

Learn more | View